Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a line of novel small molecule therapeutics to address the needs of patients with immuno-inflammatory diseases. The company is headquartered in Wayne, Pennsylvania.
| Revenue (TTM) | $8.22M |
| Gross Profit (TTM) | $-62.27M |
| EBITDA | $-85.53M |
| Operating Margin | -1469.00% |
| Return on Equity | -59.10% |
| Return on Assets | -29.00% |
| Revenue/Share (TTM) | $0.06 |
| Book Value | $0.85 |
| Price-to-Book | 4.57 |
| Price-to-Sales (TTM) | 68.07 |
| EV/Revenue | 58.16 |
| EV/EBITDA | 0.28 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -8.30% |
| Shares Outstanding | $154.99M |
| Float | $103.48M |
| % Insiders | 2.18% |
| % Institutions | 84.39% |
Volatility is currently contracting
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.
- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic Dermatitis (AD) - - Positive Primary Analysis Results Announced from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 in AD and Asthma - - Strong Cash Runway Expected to Enable Development of Pipeline Through the First Half of 2029 - WAYNE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2026 and provided a corporate and clinical update.
WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an underwritten offering of 7,785,714 shares of its common stock at a price of $3.50 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 6,500,000 shares of common stock at a purchase price of $3.49999 per share, which equals the offering price per share of the common stock less the $0.00001 exercise price per share of each pre-funded warrant. All of the shares of common stock and the pre-funded warrants are to be sold by Aclaris.
Aclaris Therapeutics Announces Positive Phase 1b Proof-of-Concept Primary Analysis Results for its Anti-TSLP/IL-4Rα Bispecific ATI-052 in Atopic Dermatitis
Here is how Aclaris Therapeutics (ACRS) and Glaukos (GKOS) have performed compared to their sector so far this year.
Aclaris (ACRS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
WAYNE, Pa., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Thursday, September 10, 2026, at 2:45 PM ET, Aclaris' Chief Executive Officer Dr. Neal Walker will participate in a fireside chat during the 2026 Cantor Global Healthcare Conference in New York, NY.
The consensus price target hints at a 69.2% upside potential for Aclaris (ACRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.13 per share a year ago.
Aclaris (ACRS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on ACRS and any ticker you trade — then tracks every position and per-strategy win rate.
